Egypt
· Delayed Price · Currency is EGP GlaxoSmithKline S.A.E Statistics
Total Valuation
EGX:BIOC has a market cap or net worth of EGP 4.05 billion. The enterprise value is 3.81 billion.
| Market Cap | 4.05B |
| Enterprise Value | 3.81B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Jul 18, 2024 |
Share Statistics
EGX:BIOC has 83.51 million shares outstanding. The number of shares has increased by 0.10% in one year.
| Current Share Class | 83.51M |
| Shares Outstanding | 83.51M |
| Shares Change (YoY) | +0.10% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.43M |
Valuation Ratios
The trailing PE ratio is 27.64.
| PE Ratio | 27.64 |
| Forward PE | n/a |
| PS Ratio | 1.15 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 63.76 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.96, with an EV/FCF ratio of -71.91.
| EV / Earnings | 26.03 |
| EV / Sales | 1.08 |
| EV / EBITDA | 9.96 |
| EV / EBIT | 11.65 |
| EV / FCF | -71.91 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.46 |
| Quick Ratio | 0.31 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | -1.53 |
| Interest Coverage | 24.21 |
Financial Efficiency
Return on equity (ROE) is 7.46% and return on invested capital (ROIC) is 9.88%.
| Return on Equity (ROE) | 7.46% |
| Return on Assets (ROA) | 4.75% |
| Return on Invested Capital (ROIC) | 9.88% |
| Return on Capital Employed (ROCE) | 15.80% |
| Revenue Per Employee | 4.40M |
| Profits Per Employee | 183,108 |
| Employee Count | 800 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, EGX:BIOC has paid 190.97 million in taxes.
| Income Tax | 190.97M |
| Effective Tax Rate | 56.59% |
Stock Price Statistics
The stock price has increased by +72.96% in the last 52 weeks. The beta is 0.87, so EGX:BIOC's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +72.96% |
| 50-Day Moving Average | 41.53 |
| 200-Day Moving Average | 39.55 |
| Relative Strength Index (RSI) | 66.25 |
| Average Volume (20 Days) | 249,424 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EGX:BIOC had revenue of EGP 3.52 billion and earned 146.49 million in profits. Earnings per share was 1.75.
| Revenue | 3.52B |
| Gross Profit | 733.72M |
| Operating Income | 327.38M |
| Pretax Income | 337.45M |
| Net Income | 146.49M |
| EBITDA | 369.98M |
| EBIT | 327.38M |
| Earnings Per Share (EPS) | 1.75 |
Balance Sheet
The company has 317.23 million in cash and 81.20 million in debt, giving a net cash position of 236.02 million or 2.83 per share.
| Cash & Cash Equivalents | 317.23M |
| Total Debt | 81.20M |
| Net Cash | 236.02M |
| Net Cash Per Share | 2.83 |
| Equity (Book Value) | 2.01B |
| Book Value Per Share | 24.12 |
| Working Capital | 1.30B |
Cash Flow
In the last 12 months, operating cash flow was 63.50 million and capital expenditures -116.52 million, giving a free cash flow of -53.03 million.
| Operating Cash Flow | 63.50M |
| Capital Expenditures | -116.52M |
| Free Cash Flow | -53.03M |
| FCF Per Share | -0.63 |
Margins
Gross margin is 20.85%, with operating and profit margins of 9.30% and 4.16%.
| Gross Margin | 20.85% |
| Operating Margin | 9.30% |
| Pretax Margin | 9.59% |
| Profit Margin | 4.16% |
| EBITDA Margin | 10.51% |
| EBIT Margin | 9.30% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.55%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 1.55% |
| Dividend Growth (YoY) | -80.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 52.00% |
| Buyback Yield | -0.10% |
| Shareholder Yield | 1.45% |
| Earnings Yield | 3.62% |
| FCF Yield | -1.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EGX:BIOC has an Altman Z-Score of 2.24 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 4 |